All In Biotech

Drug Trial Radar · NCT01297452

BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors

A Phase I Study of BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Mar 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

Feb 15, 2011

Primary completion

Mar 29, 2017

Study completion Mar 29, 2017

Sponsor

Lead sponsor
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novartis Pharmaceuticals; Sai Life Sciences
First posted
Feb 16, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out the good and bad effects that occur when BKM120 is added to standard chemotherapy with carboplatin and paclitaxel.

Conditions

  • Solid Tumors

Interventions

  • BKM120 days 1 - 21 plus paclitaxel + carboplatinDrug

    Patients will receive oral daily BKM120 (days 1 - 21, per dose escalation scheme) plus paclitaxel (175 mg/m2 intravenously, day 1) + carboplatin (AUC 5 intravenously, day 1)on a 21-day cycle. Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle.

  • BKM120 (days 1 - 28, ) plus paclitaxel + carboplatinDrug

    Patients will receive oral daily BKM120 (days 1 - 28, per dose escalation scheme) plus paclitaxel (80 mg/m2 intravenously, days 1, 8 and 15) + carboplatin (AUC 5 intravenously, day 1) on a 28-day cycle.

  • BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)Drug

    BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT.A

  • BKM120, Paclitaxel + CarboplatinDrug

    BKM120 100 mg per oral, days 1 - 21 Paclitaxel (175 mg/m2) intravenously on Day 1 Carboplatin (AUC 5) intravenously on Day 1 EXPANSION COHORT B

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To establish the phase II recommended dose of daily oral BKM120Time frame: 2 years
  2. EXPANSION COHORT A:To evaluate the safety and tolerability of daily oral BKM120 (100 mg) + paclitaxel (200 mg/m2) + carboplatin (AUC 6), both given intravenously (IV) on day 1 of a 21-day cycle, with pegfilgrastim supportTime frame: 2 years
  3. EXPANSION COHORT B: To obtain a preliminary description of efficacy of the regimen established in Group 1 among patients with tumors harboring PTEN mutation or homozygous deletion.Time frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Memorial Sloan Kettering Cancer Center

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.